Pulmonx Corporation (LUNG)

Market Cap	289.03M
Revenue (ttm)	68.68M
Net Income (ttm)	-60.84M
Shares Out	38.54M
EPS (ttm)	-1.60
PE Ratio	n/a
Forward PE	28.33
Dividend	n/a
Ex-Dividend Date	n/a

Volume	528,070
Open	7.43
Previous Close	7.43
Day's Range	7.21 - 7.51
52-Week Range	7.21 - 14.84
Beta	0.60
Analysts	Strong Buy
Price Target	15.57 (+107.6%)
Earnings Date	May 1, 2024

About LUNG

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitat...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Oct 1, 2020
• Employees: 279
• Stock Exchange: NASDAQ
• Ticker Symbol: LUNG

Financial Performance

In 2023, Pulmonx's revenue was $68.68 million, an increase of 27.98% compared to the previous year's $53.66 million. Losses were -$60.84 million, 3.26% more than in 2022.

Analyst Forecast

According to 7 analysts, the average rating for LUNG stock is "Strong Buy." The 12-month stock price forecast is $15.57, which is an increase of 107.60% from the latest price.

Price Target

$15.57

(107.60% upside)

Analyst Consensus: Strong Buy